Eterna Therapeutics Inc (ERNA) - Total Liabilities

Latest as of September 2025: $2.60 Million USD

Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) has total liabilities worth $2.60 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Eterna Therapeutics Inc cash flow conversion to assess how effectively this company generates cash.

Eterna Therapeutics Inc - Total Liabilities Trend (2006–2024)

This chart illustrates how Eterna Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See ERNA book value for net asset value and shareholders' equity analysis.

Eterna Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Eterna Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Norben Tea & Exports Limited NSE:NORBTEAEXP	India	Rs116.28 Million
Saraswati Griya Lestari Tbk JK:HOTL	Indonesia	Rp78.10 Billion
Palamina Corp V:PA	Canada	CA$1.64 Million
Snipp Interactive Inc V:SPN	Canada	CA$10.10 Million
Radiant Utama Interinsco Tbk JK:RUIS	Indonesia	Rp710.69 Billion
Biovica International AB (publ) ST:BIOVIC-B	Sweden	Skr31.14 Million
AEON Biopharma, Inc. NYSE MKT:AEON	USA	$28.61 Million

Liability Composition Analysis (2006–2024)

This chart breaks down Eterna Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ERNA market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.58	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.73	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.42	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Eterna Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Eterna Therapeutics Inc (2006–2024)

The table below shows the annual total liabilities of Eterna Therapeutics Inc from 2006 to 2024.

Year	Total Liabilities	Change
2024-12-31	$3.57 Million	-92.39%
2023-12-31	$46.90 Million	+361.06%
2022-12-31	$10.17 Million	+68.94%
2021-12-31	$6.02 Million	+14.75%
2020-12-31	$5.25 Million	-48.48%
2019-12-31	$10.19 Million	+28.16%
2018-12-31	$7.95 Million	-27.98%
2017-12-31	$11.03 Million	-15.56%
2016-12-31	$13.07 Million	+0.72%
2015-12-31	$12.97 Million	+14.38%
2014-12-31	$11.34 Million	+81.36%
2013-12-31	$6.25 Million	+31.35%
2012-12-31	$4.76 Million	-10.10%
2011-12-31	$5.30 Million	+44.57%
2010-12-31	$3.66 Million	-24.90%
2009-12-31	$4.88 Million	+24.59%
2008-12-31	$3.92 Million	-26.00%
2007-12-31	$5.29 Million	-33.81%
2006-12-31	$8.00 Million	--

About Eterna Therapeutics Inc

NASDAQ:ERNA USA Biotechnology

Market Cap

$110.89 Million

Market Cap Rank

#26798 Global

#5335 in USA

Share Price

$3.81

Change (1 day)

+2482.99%

52-Week Range

$0.15 - $3.81

All Time High

$1570.00